Every branded drug in America has a price that virtually no one pays. It is published, cited in earnings calls, printed in investor decks, referenced in formulary negotiations, and reported in media coverage of pharmaceutical costs. It is called the Wholesale Acquisition Cost, and it functions less as a price than as a coordinate — a fixed point from which everything else is measured.
WAC is the manufacturer’s price to wholesalers or direct purchasers before any discounts or rebates. That final clause does the heavy lifting. Before any discounts or rebates means before the 340B program’s mandatory ceiling prices, before Medicaid’s statutory rebates, before commercial rebates negotiated by pharmacy benefit managers, before prompt-pay discounts, before chargebacks to group purchasing organizations, and before the dozens of other concessions that collectively constitute the gross-to-net waterfall. WAC is the top of the waterfall. The water that reaches the bottom looks nothing like what went over the edge.
The pharmaceutical industry did not stumble into this arrangement accidentally. WAC serves a structural purpose that persists precisely because it is detached from transactional reality. For manufacturers, a high WAC creates negotiating headroom. Offering a PBM a thirty percent rebate off WAC sounds generous until one recognizes that WAC was set with that rebate already priced in. The discount is a feature, not a concession. For payers, WAC provides a common denominator for contracting — a shared reference point that simplifies negotiations across thousands of NDCs even if the number itself is arbitrary. For wholesalers, the spread between WAC and the actual acquisition cost represents margin. Everyone benefits from the fiction, which is why no one dismantles it.
The gap between WAC and actual transaction prices has widened steadily. In the early 2000s, the average gross-to-net discount for branded drugs hovered around fifteen to twenty percent. By the mid-2020s, industry analyses place the average closer to fifty percent for many therapeutic categories, and some specialty drugs carry gross-to-net spreads exceeding sixty percent. A drug with a WAC of $10,000 per month may generate net revenue of $4,000 or less per patient after all concessions clear. The list price and the realized price have diverged to the point where they describe different economic objects.
This divergence creates a peculiar information asymmetry. Manufacturers know their net prices with granularity — by channel, by payer, by quarter. That information is confidential. What is public is WAC, which tells you almost nothing about what anyone actually pays. Investors analyzing pharmaceutical companies must model the gross-to-net spread using fragmentary data, analyst estimates, and inference from quarterly filings that disclose net revenue but not the composition of discounts that produced it. The exercise is less financial analysis than forensic reconstruction.
For patients, the consequences are more immediate and less abstract. Cost-sharing structures in many insurance plans — particularly high-deductible designs and coinsurance models — calculate the patient’s obligation as a percentage of WAC or a WAC-derived benchmark. A patient with a twenty percent coinsurance on a drug with a $10,000 WAC owes $2,000, even if the payer’s net cost after rebates is $4,000. The patient’s share exceeds what the insurer actually paid. This arithmetic has been documented extensively, criticized repeatedly, and reformed minimally.
The persistence of WAC as the gravitational center of drug pricing reflects something deeper than institutional inertia. It reflects the absence of a viable alternative that all stakeholders would accept. Net price, which strips away most concessions, would be more transparent — but manufacturers guard net pricing data as proprietary competitive intelligence, and disclosure would restructure competitive dynamics in ways that many stakeholders actively resist. Average sales price, which CMS calculates from manufacturer-reported data, comes closer to transactional reality but applies only to physician-administered drugs reimbursed under Medicare Part B and updates with a two-quarter lag. NADAC approximates actual pharmacy acquisition costs but covers only retail community pharmacies and excludes the specialty channel entirely.
Each alternative reveals something that WAC conceals, but none replaces it as a universal reference. WAC endures because it is the only pricing metric that is public, applicable across all channels, updated in near real-time by manufacturers, and accepted as a contractual anchor by all parties. Its accuracy is beside the point. Its universality is the point.
The Inflation Reduction Act introduced a new pricing concept — the Maximum Fair Price — that deliberately bypasses WAC as a reference. MFP is bounded by a percentage of a drug’s non-federal average manufacturer price, not by WAC. This is a structural choice. By anchoring negotiated Medicare prices to AMP rather than WAC, the IRA’s architects avoided building on a number that everyone knows is inflated. Whether MFP will erode WAC’s dominance over time or simply add another layer to an already baroque pricing architecture remains an open question.
The pharmaceutical industry’s relationship with WAC resembles a fiat currency backed by nothing but collective agreement. The number has no intrinsic meaning — it does not reflect manufacturing cost, therapeutic value, market-clearing price, or any other economic fundamental. It means what everyone agrees it means, which is that it is the number from which discounts are calculated. The discounts are real. The starting point is not.
There is a case to be made that this arrangement, for all its opacity, is not entirely dysfunctional. WAC provides a stable reference that allows complex multi-party negotiations to proceed without requiring disclosure of proprietary pricing information at each step. It enables payers to benchmark across manufacturers and therapeutic categories using a common scale. It gives manufacturers pricing flexibility without requiring them to renegotiate every contract when market dynamics shift. The system works, in the sense that transactions clear and drugs reach patients. Whether it works well, or fairly, or efficiently, is a different question — one that WAC, by design, cannot answer.
